Vir Biotechnology Inc (VIR)

Return on assets (ROA)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019
Net income (ttm)	US$ in thousands	-615,117	-600,747	-262,022	-143,740	515,837	1,142,694	1,077,810	1,216,116	528,584	-102,319	-297,356	-390,336	-298,665	-256,787	-220,492
Total assets	US$ in thousands	1,919,060	2,044,900	2,243,870	2,665,940	2,802,090	2,695,970	2,618,990	2,887,130	1,954,270	1,210,210	1,057,580	1,135,580	918,761	943,259	672,238	477,114	512,071	422,642
ROA		-32.05%	-29.38%	-11.68%	-5.39%	18.41%	42.39%	41.15%	42.12%	27.05%	-8.45%	-28.12%	-34.37%	-32.51%	-27.22%	-32.80%

December 31, 2023 calculation

ROA = Net income (ttm) ÷ Total assets
= $-615,117K ÷ $1,919,060K
= -32.05%

To analyze the return on assets (ROA) of Vir Biotechnology Inc based on the provided data, we observe a fluctuating trend over the past eight quarters. The ROA ranged from -32.05% in Q4 2023 to a peak of 42.39% in Q3 2022.

The negative ROA figures in the recent quarters (Q4 2023, Q3 2023, and Q2 2023) indicate that the company's net income generated from its assets has been insufficient to cover its total assets, resulting in a net loss in those periods. This may raise concerns about the company's operational efficiency and profitability.

Conversely, the positive ROA values seen in the earlier quarters (Q4 2022, Q3 2022, Q2 2022, and Q1 2022) suggest that Vir Biotechnology Inc was able to generate higher net income relative to its total assets, indicating better profitability and asset utilization during that time.

Overall, the fluctuating trend in ROA points to varying levels of efficiency and profitability in utilizing assets over the analyzed period. Further investigation into the company's financial performance and operational strategies may provide additional insights into the factors influencing these ROA fluctuations.